Rectal toxicity after permanent iodine-125 seed implantation: Nationwide cohort study in Japan (J-POPS)
| Autor: | Nobumichi Tanaka, Hidetoshi Yamanaka, Takushi Dokiya, Shinsuke Kojima, Masanori Fukushima, Shinichiro Maruo, Toshio Ohashi, Atsunori Yorozu, Shiro Saito, Norihisa Katayama |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Gynecology
Cancer Research medicine.medical_specialty business.industry medicine.medical_treatment Cancer Common Terminology Criteria for Adverse Events Odds ratio Logistic regression medicine.disease Confidence interval Radiation therapy Prostate cancer Oncology Internal medicine medicine business Cohort study |
| Zdroj: | Journal of Clinical Oncology. 32:73-73 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 73 Background: The purpose of this report is to describe acute and late rectal toxicities and to evaluate factors associated with rectal toxicity in permanent seed implantation (PI) patients enrolled in a nationwide cohort study in Japan. Methods: A total of 2,339 patients in 46 institutes were evaluated. They were treated in the nationwide cohort study entitled Japanese Prostate Cancer Outcome Study of Permanent I-125 Seed Implantation (J-POPS) during the first two years, until June 2007. Rectal toxicities were evaluated using the National Cancer Institute - Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, which were obtained at 3, 12, 24, and 36 months after completion of radiotherapy. The odds ratios (OR) of factors associated with greater than or equal to grade 2 rectal toxicity were calculated using a logistic regression model, and the 95% confidence intervals (CI) were estimated. Results: Greater than or equal to grade 2 rectal toxicities were seen in 2.8% of all patients (1.7% in the PI monotherapy group and 6.4% in the external beam radiation therapy [EBRT] combination therapy group). On multivariate analysis, among all patients, greater than or equal to grade 2 rectal toxicity was associated with rectal volumes receiving 100% of the prescribed dose (R100) (OR, 1.93; 95% CI, 1.39–2.68) and EBRT addition (OR, 3.00; 95% CI, 1.39–6.32). R100 in the PI monotherapy group (OR, 1.67; 95% CI, 1.06–2.64), and R100 (OR, 2.07; 95% CI, 1.30–3.30) and interactive planning (OR, 0.46; 95% CI, 0.23–0.92) in the EBRT combination therapy group were also associated with greater than or equal to grade 2 toxicity. Greater than or equal to grade 2 toxicity was seen in 3.7% and 1.4% of patients with R100 greater than or equal to 1 ml and R100 less than 1 ml, respectively, in the PI monotherapy group (OR, 2.78; 95% CI, 1.28–6.05) and in 14.1% and 5.4% of patients with R100 greater than or equal to 1 ml and R100 less than 1 ml, respectively, in the EBRT combination therapy group (OR, 2.88; 95% CI, 1.28–6.45). Conclusions: Rectal toxicity was relatively limited compared to other reports. For Japanese PI patients, R100 should be less than 1 ml, both in PI monotherapy and in EBRT combination therapy, and interactive planning should be performed for EBRT combination therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|